Keyphrases
Immune Checkpoint Inhibitors
100%
Immune-related Adverse Events
46%
Checkpoint Inhibitors
28%
Adverse Events
26%
Melanoma
24%
Cancer Therapy
23%
Cancer Immunotherapy
22%
In Cancer
21%
Inflammatory Arthritis
21%
Pre-existing Autoimmune Disease
16%
Rheumatic Immune-related Adverse Events
16%
Meta-analysis
16%
Systematic Literature Review
16%
Immune Checkpoint Inhibitor Therapy
15%
Overall Survival
13%
Confidence Interval
13%
Corticosteroids
12%
Patients with Cancer
11%
United States
11%
Antiphospholipid Antibodies
10%
Clinical Practice Recommendations
10%
Arthritis
10%
Immune Checkpoint
10%
Immune Response
10%
Cardiovascular Toxicity
10%
Renal Toxicity
10%
Systemic Juvenile Idiopathic Arthritis (sJIA)
10%
Systematic Meta-analysis
10%
Immune Toxicity
10%
Multinational Association of Supportive Care in Cancer
10%
PD-1 Blockade
10%
HIV-associated
10%
Classical Hodgkin Lymphoma
10%
Cancer Patients
10%
Monotherapy
9%
Immunosuppressive Agents
9%
Rheumatoid Arthritis
8%
Pathologic
8%
Clinical Outcomes
7%
Progression-free Survival
7%
People Living with HIV (PLHIV)
7%
Myositis
7%
Checkpoint Inhibitor Therapy
7%
Nivolumab
7%
Risk Ratio
6%
Cancer Treatment
6%
Disease Activity
6%
Hepatocellular Carcinoma
6%
Autoimmune Disease
6%
Multicenter Retrospective Study
6%
Medicine and Dentistry
Immune Checkpoint Inhibitor
88%
Malignant Neoplasm
44%
Adverse Event
37%
Immune-Related Adverse Events
33%
Systematic Review
32%
Immunity
30%
Nephrotoxicity
18%
Cancer Immunotherapy
17%
Immunotherapy
16%
Human immunodeficiency virus
16%
Melanoma
15%
Overall Survival
14%
Cancer Therapy
13%
Interstitial Nephritis
13%
Acute Kidney Injury
12%
Immune Checkpoint Blockade
10%
Supportive Care
10%
Juvenile Idiopathic Arthritis
10%
Autoimmune Disease
10%
Cardiovascular System
10%
Infliximab
10%
Classical Hodgkin Lymphoma
10%
Rheumatoid Arthritis
10%
Inflammatory Arthritis
10%
Biopsy Technique
10%
Retrospective Study
9%
Monotherapy
8%
Progression Free Survival
8%
Myositis
7%
Neoplasm
7%
Oncology
7%
Nivolumab
7%
Squamous Cell Carcinoma
7%
Cancer
6%
Disease Activity
6%
Arthritis
6%
Hepatocellular Carcinoma
6%
Osteoporosis
5%
Nephritic Syndrome
5%
Infection
5%
Urogenital Tract Tumor
5%
Penis Cancer
5%
Solid Organ Transplantation
5%
Allogeneic Hematopoietic Stem Cell Transplantation
5%
Quality of Life
5%
Renal Vasculitis
5%
Cardiovascular Disease
5%
Cyclophosphamide
5%
Osteoclast Differentiation Factor
5%
Hand Grip
5%
Pharmacology, Toxicology and Pharmaceutical Science
Immune Checkpoint Inhibitor
73%
Malignant Neoplasm
60%
Adverse Event
36%
Inflammatory Arthritis
19%
Rheumatoid Arthritis
19%
HIV
13%
Myositis
12%
Antiphospholipid Antibody
12%
Autoimmune Disease
11%
Immunotherapy
11%
Arthritis
10%
Infliximab
10%
Nephrotoxicity
10%
Observational Study
8%
Melanoma
8%
Thromboembolism
7%
Diseases
7%
Monotherapy
7%
Acute Kidney Failure
6%
Myasthenia gravis
6%
Infection
6%
Virus Infection
5%
Tumor Necrosis Factor Inhibitor
5%
Classical Hodgkin Lymphoma
5%
Cyclophosphamide
5%
Enterocolitis
5%
Myelodysplastic Syndrome
5%
2,5-Dimethoxy-4-iodoamphetamine
5%
Interstitial Nephritis
5%
Antiphospholipid Syndrome
5%
Solid Malignant Neoplasm
5%
Acute Graft Versus Host Disease
5%
Systemic Lupus Erythematosus
5%
Acute Myeloid Leukemia
5%
Graft Versus Host Reaction
5%
Methotrexate
5%
Cardiovascular Disease
5%
Fragility Fracture
5%
Hepatitis C Virus
5%